Regulatory Strategic Planning Flashcards

Which tool is most useful for proactively identifying regulatory risks before a product submission?

Answer: FMEA (Failure Mode and Effects Analysis) of the regulatory strategy

FMEA applied to regulatory strategy systematically identifies potential failure modes in the regulatory plan and their impact on approval timelines.

A company seeks approval in both the EU and US simultaneously. The primary benefit of using the ICH CTD format is:

Answer: It provides a harmonized submission structure accepted by both FDA and EMA

The ICH CTD (Common Technical Document) provides a standardized format accepted by FDA, EMA, and other ICH member agencies, reducing duplication in preparing dossiers.

When should a regulatory strategy be formally reassessed during product development?

Answer: At predefined decision points and when significant new data emerge

Regulatory strategy should be reassessed at defined decision gates (e.g., end-of-Phase 2) and whenever significant new clinical, safety, or competitive data emerge.

Which FDA program is specifically designed to expedite development and review of drugs for serious conditions where preliminary evidence shows advantage over available therapy?

Answer: Fast Track Designation

Fast Track Designation is designed to facilitate development and expedite review of drugs for serious conditions that demonstrate potential to address unmet medical needs.

In EU regulatory strategy, the primary purpose of a Scientific Advice procedure with EMA is:

Answer: To gain EMA guidance on data requirements before a marketing authorization application

EMA Scientific Advice provides non-binding guidance on the data package and study designs needed to support a future marketing authorization application.

A biosimilar regulatory strategy differs from a standard biologic strategy primarily because it requires:

Answer: A totality-of-evidence approach demonstrating no clinically meaningful differences from the reference product

Biosimilar approval relies on a totality-of-evidence approach showing no clinically meaningful differences from the reference product in terms of safety, purity, and potency.

The concept of 'regulatory intelligence' in strategic planning involves:

Answer: Monitoring competitor regulatory filings and agency guidance to inform strategy

Regulatory intelligence involves systematically monitoring regulatory agency activities, competitor filings, guidance documents, and industry trends to inform and update regulatory strategy.